NEW YORK (GenomeWeb) – Investment bank BTIG initiated coverage of NanoString Technologies on Monday with a Buy rating, saying new market opportunities could await the company's nCounter platform. 

BTIG analyst Dane Leone had a price target of $16 on NanoString's stock and estimated the company's full-year 2015 revenues at $61 million with a loss per share of $1.90. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.